{
    "clinical_study": {
        "@rank": "38550", 
        "acronym": "ICGguidedPDT", 
        "arm_group": {
            "arm_group_label": "Visudyne", 
            "arm_group_type": "Experimental", 
            "description": "Visudyne half fluence- 1 treatment with the possibility of a second treatment."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research is to use an approved drug(Visudyne) for neovascular\n      age-related macular degeneration, which is essentially choroidal neovascularization for\n      permeability and vascular proliferation for the retinal circulation, to treat another\n      permeable abnormality - retinal capillary abnormalities - located eccentric to the central\n      portion of the macula or in the foveal region."
        }, 
        "brief_title": "ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Retinal Vascular Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Vascular Diseases", 
                "Retinal Vasculitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will include 30 patients who were diagnosed with retinal capillary abnormalities\n      and include 2 follow-up visits at 6 and 12 months post-procedure to determine if the\n      treatment has been effective in treating their disorder.  It is anticipated that\n      approximately half of the patients will require an additional treatment.  Patients will be\n      enrolled from our patient population and be 50 years of age and older, male or female.\n      Pregnant women or women of normal child bearing age will be excluded since there are no\n      adequate and well-controlled studies on the use of photodynamic therapy in pregnant women.\n      Any retinal vascular abnormality that has a standard of care method of treatment will also\n      be excluded from the study population."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\u2022 Individuals that are 50 years of age and older.\n\n          -  Patients with retinal capilary abnormalities/vascular diseases such as macular\n             telangiectasia type I and type II, retinal arteriolar macroanurysms, and retinal\n             angiomous proliferation (RAP).\n\n          -  Patients with diabetic retinopathy and branch retinal vein occlusions\n\n          -  Other patients who are non-responders to approved treatment methods\n\n        Exclusion Criteria:\n\n          -  Patients whose diseases have approved methods of treatment.\n\n          -  Pregnant women or women of normal child bearing age."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974622", 
            "org_study_id": "ICG- guided PDT Study"
        }, 
        "intervention": {
            "arm_group_label": "Visudyne", 
            "description": "Half fluence verteporfin", 
            "intervention_name": "Visudyne", 
            "intervention_type": "Drug", 
            "other_name": "Verteporfin"
        }, 
        "intervention_browse": {
            "mesh_term": "Verteporfin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "contact": {
                "email": "layannuzzi@gmail.com", 
                "last_name": "Lawrence A. Yannuzzi, M.D.", 
                "phone": "212-605-3777"
            }, 
            "contact_backup": {
                "email": "ibarbazetto@gmail.com", 
                "last_name": "Irene Barbazetto, M.D.", 
                "phone": "(212) 861-9797"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10022"
                }, 
                "name": "Vitreous Retina Macula Consultants of New York"
            }, 
            "investigator": [
                {
                    "last_name": "Lawrence A. Yannuzzi, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Irene Barbazetto, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Indocyanine Green Angiography-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities.", 
        "overall_official": {
            "affiliation": "Northshore LIJ/MEETH", 
            "last_name": "Lawrence A. Yannuzzi, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The drug, approved for are-related macular degeneration should also prove effective for other permeable conditions, such as retinal capillary/vascular abnormalities that lead to macular edemas such as macular  telangiectasia type I and type II, retinal arteriolar macroanurysms, and retinal angiomatous proliferation (RAP), which is a variant of neovascular age-related macular degeneration. These diseases currently have no available approved alternative treatment.", 
            "measure": "Improvement and/or stabilization of disease.", 
            "safety_issue": "No", 
            "time_frame": "1-2 years"
        }, 
        "reference": {
            "PMID": "22451952", 
            "citation": "Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM Jr, Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. 2003. Retina. 2012 Feb;32 Suppl 1:288-98."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974622"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Manhattan Eye, Ear & Throat Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Manhattan Eye, Ear & Throat Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}